Toward efficient trials in colorectal cancer: The ARCAD clinical trials program

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 527-530

  De Gramont, Aimery ^a   Haller, Daniel G ^b   Sargent, Daniel J ^c   Tabernero, Josep ^d   Matheson, Alastair ^e   Schilsky, Richard L ^f  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MAYO CLINIC   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e Foundation ARCAD   (France)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; IRINOTECAN; OXALIPLATIN; RALTITREXED; UFT;

CANCER RESEARCH; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE COURSE; DRUG TARGETING; HUMAN; IMMUNOMODULATION; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; COLORECTAL TUMOR; MEDICAL RESEARCH; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PROGRAM DEVELOPMENT; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; PROGRAM DEVELOPMENT;

EID: 77449087794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.2544     Document Type: Note

References (39)

1. Schilsky RL: End points in cancer clinical trials and the drug approval process. Clin Cancer Res 8:935-938, 2002
2. Schilsky RL: Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol 27:3725-3730, 2009
3. US Food and Drug Administration: Innovation/Stagnation: Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/ initiatives/criticalpath/whitepaper.html
4. Cocconi G, Cunningham D, Van Cutsem E, et al: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16:2943-2952, 1998 (Pubitemid 28417413)
5. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
6. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
7. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
8. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001 (Pubitemid 32366981)
9. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
10. Carmichael J, Popiela T, David Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20:3617-3627, 2002 (Pubitemid 34983221)
11. Douillard JY, Paulo M, Hoff PM, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer J Clin Oncol 20:3605-3616, 2002
12. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
13. Ibrahim A, Hirschfeld S, Cohen MH, et al: FDA drug approval summaries: Oxaliplatin. Oncologist 9:8-12, 2004 (Pubitemid 38134009)
14. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
15. Laurent-Puig P, Taieb J: Lessons from Tarceva in pancreatic cancer: Where are we now, and how should future trials be designed in pancreatic cancer? Curr Opin Oncol 20:454-458, 2008
16. Buyse M, Burzykowski T, Carroll K, et al: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218-5224, 2007 (Pubitemid 350232253)
17. Sargent DJ, Hayes DF: Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol 26:1922-1923, 2008
18. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987-1992, 2008
19. US Food and Drug Administration: Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/ cder/Guidance/7478fnl.pdf
20. Fleming TR, Rothmann MD, Lu HL: Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 27:2874-2880, 2009
21. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24:394-400, 2006
22. Chibaudel B, Maindrault-Goebel F, Lledo G, et al: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer?: The GERCOR OPTIMOX2 study. J Clin Oncol 27:5727-5733, 2009
23. Labianca R, Floriani I, Cortesi E, et al: Alternating versus continuous "FOLFIRI" in advanced colorectal cancer: A randomized "GISCAD" trial. J Clin Oncol 24:147s, 2006 (suppl 3505)
24. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034, 2009
25. Sawyers CL: The cancer biomarker problem. Nature 452:548-552, 2008
26. Clarke M: Meta-analyses of adjuvant therapies for women with early breast cancer: The Early Breast Cancer Trialists' Collaborative Group overview. Ann Oncol 17:S59-S62, 2006 (suppl 10)
27. Krause M, Baumann M: Clinical biomarkers of kinase activity: Examples from EGFR inhibition trials. Cancer Metastasis Rev 27:387-402, 2008
28. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166-1169, 2007
29. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
30. Loupakis F, Pollina L, Stasi I, et al: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622-2629, 2009
31. Longo R, Gasparini G: Anti-VEGF therapy: The search for clinical biomarkers. Expert Rev Mol Diagn 8:301-314, 2008 (Pubitemid 351724709)
32. Altar CA: The Biomarkers Consortium: On the critical path of drug discovery. Clin Pharmacol Ther 83:361-364, 2008
33. US Food and Drug Administration: FDA Critical Path Initiative. http://www.fda.gov/oc/initiatives/criticalpath
34. Woodcock J, Woosley R: The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1-12, 2008 (Pubitemid 351287920)
35. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
36. Rabaglio M, Aebi S, Castiglione-Gertsch M: Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 8:940-949, 2007
37. National Cancer Institute. http://www.cancer.gov/researchandfunding
38. Abrams JD, Murgo A, Christian MC: NCI's cancer therapy evaluation program: A commitment to treatment trials, in Leong SPL (ed): Cancer Clinical Trials: Proactive Strategies. New York, NY, Springer, 2007, pp 32-50
39. Sargent DJ, Patiyil S, Yothers G: End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25:4569-4574, 2007 (Pubitemid 350035314)